CHINA MEDICAL UNIVERSITY HOSPITAL
🇹🇼Taiwan
Avance Clinical Expands Asia-Pacific Footprint with Four Strategic Partnerships in Taiwan
• Avance Clinical, a global Contract Research Organization, has signed Memorandums of Understanding with four premier Taiwanese medical institutions, strengthening its GlobalReady model for biotech companies.
• The partnerships with Taichung Veterans General Hospital, Taipei Medical University, China Medical University Hospital, and Kaohsiung Medical University Chung-Ho Memorial Hospital provide US biotechs access to Taiwan's advanced healthcare infrastructure and diverse patient populations.
• This strategic expansion leverages Taiwan's regulatory efficiency and clinical expertise, particularly in areas like CAR-T cell immunotherapy, to accelerate innovative treatment development for patients worldwide.
St Vincent's Melbourne and CMUH Forge International Partnerships to Advance Clinical Research
• St Vincent's Hospital Melbourne has established a partnership with China's Sichuan Provincial People's Hospital to conduct joint multi-center clinical trials focusing on drugs, medical devices, and digital solutions.
• China Medical University Hospital (CMUH) signed an MOU with AbbVie in December 2024, combining CMUH's clinical research capabilities with AbbVie's global R&D resources to enhance trial efficiency in the Asia Pacific region.
• Both partnerships include knowledge exchange programs, with St Vincent's focusing on research nurse training while CMUH-AbbVie collaboration aims to optimize trial processes and improve patient recruitment.
Novel Patient-Derived Tumor Spheroid Model Shows Promise for Personalized Brain Cancer Treatment
Chinese researchers have developed an innovative patient-derived tumor spheroid (PDTS) model that could enhance precision medicine approaches for brain cancer patients. The study, conducted at China Medical University Hospital, demonstrates the potential of using 3D biomimetic platforms to test drug responses in metastatic brain tumors, offering a new tool for personalizing cancer treatment strategies.
Sacituzumab Govitecan Demonstrates Efficacy in HR+/HER2- Metastatic Breast Cancer
• Sacituzumab govitecan (SG) significantly improved progression-free survival (PFS) compared to chemotherapy in patients with HR+/HER2- metastatic breast cancer.
• The phase 3 EVER-132-002 trial included patients who had received two to four prior chemotherapy regimens, showing SG's benefit in heavily pre-treated populations.
• SG demonstrated a manageable safety profile, supporting its potential as a valuable treatment option for this patient population in regions including mainland China, Republic of Korea and Taiwan.
• The study's findings contribute to addressing the unmet need for effective therapies in HR+/HER2- metastatic breast cancer, particularly after multiple lines of treatment.
© Copyright 2025. All Rights Reserved by MedPath